Head-to-head · free

Cyclerion Therapeutics vs LB Pharmaceuticals

KRSA vs LBRX — return on capital, cash generation, margins and balance sheet side by side.

KRSA

2 / 2

measures where KRSA leads

LBRX

0 / 2

measures where LBRX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureKRSA · FY2025LBRX · FY2025
Revenue$2.1M—
Net income(3.5M)(25.2M)
Revenue growth (yearly, multi-year)-19.3%—
Free cash flow—(35.3M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity——
Gross margin——
Operating margin——
Net debt / EBITDA4.13x8.32x

Figures are as reported by each company; latest fiscal year shown.

Where Cyclerion Therapeutics's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full KRSA profile →

Where LB Pharmaceuticals's cash went (FY2025)

Capital spending
$52000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LBRX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons